This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
National Vision (EYE) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
National Vision's (EYE) contact lens revenue growth is expected to have remained impressive in Q3 on lesser impact of store closures.
National Vision (EYE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National Vision Banks on Contact Lens Sales Amid Coronavirus Woes
by Zacks Equity Research
National Vision (EYE) sales bear the impact of unfavorable timing of unearned revenues.
Why Is National Vision (EYE) Up 18.4% Since Last Earnings Report?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Surging Earnings Estimates Signal Upside for National Vision (EYE) Stock
by Zacks Equity Research
National Vision (EYE) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
National Vision (EYE) Stock on the Rise Since Q2 Earnings Beat
by Zacks Equity Research
Investors seem to be impressed with National Vision's (EYE) better-than-expected second-quarter 2020 results despite the coronavirus-led economic crisis.
National Vision (EYE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 28.07% and 6.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy National Vision (EYE) Ahead of Earnings?
by Zacks Equity Research
National Vision (EYE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate National Vision (EYE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National Vision (EYE) Q1 Earnings Top Estimates, Margin Falls
by Zacks Equity Research
National Vision's (EYE) first-quarter 2020 results were better than expected despite the coronavirus-led economic crisis.
Here's Why You Should Add Tandem Diabetes to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strength in the diabetes business and receipt of regulatory approvals.
Walgreens' Retail Pharmacy Grows Amid Coronavirus Crisis
by Zacks Equity Research
Walgreens (WBA) registers growing demand for Retail Pharmacy & Pharmaceutical Wholesale products in Q2.
Abbott Launches Antibody Test to Detect Coronavirus Infection
by Zacks Equity Research
Abbott (ABT) launches a lab-based serology blood test to detect the presence of antibodies post the coronavirus infection.
QIAGEN Launches Assay for Cancer Patients Following FDA's Nod
by Zacks Equity Research
QIAGEN (QGEN) paves the way for metastatic CRC treatment in adults with the launch of an FDA-approved companion diagnostic test kit.
NuVasive (NUVA) Posts Q1 Preliminary Results, Withdraws View
by Zacks Equity Research
A decline in elective surgical procedures due to coronavirus outbreak weighs on NuVasive's (NUVA) preliminary revenue results for first-quarter 2020.
QIAGEN (QGEN) Reports Preliminary Revenue Results for Q1
by Zacks Equity Research
Investors remain optimistic with QIAGEN's (QGEN) first-quarter 2020 preliminary revenue results, which is likely to benefit from increased testing demand for coronavirus infection.
Illumina (ILMN) Posts Q1 Preliminary Results, Withdraws View
by Zacks Equity Research
Investors remain optimistic on Illumina's (ILMN) strong preliminary revenue results for first-quarter 2020.
Here's Why You Should Add ResMed (RMD) in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and combatting the coronavirus outbreak.
Bio-Rad Rides on International Expansion Amid Cost Concerns
by Zacks Equity Research
Each of Bio-Rad's (BIO) key segments registers solid growth across three major geographies of America, Europe and Asia.
Bio-Rad Launches Serology Test to Detect Coronavirus Antibody
by Zacks Equity Research
Bio-Rad (BIO) launches a blood-based immunoassay kit to better detect antibodies in response to SARS-CoV-2 infection.
Hologic (HOLX) Posts Q2 Preliminary Results, Withdraws View
by Zacks Equity Research
Investors remain optimistic with Hologic's (HOLX) balanced segmental preliminary revenue results for second-quarter fiscal 2020.
Integra Releases Preliminary Q1 Results, Withdraws '20 View
by Zacks Equity Research
Integra (IART) unable to measure the magnitude of total loss it has to bear out of the coronavirus-led economic damages, and hence, withdraws the full-year guidance.
Medtronic (MDT) Demonstrates Global Growth Amid Cost Concerns
by Zacks Equity Research
Medtronic's (MDT) international Diabetes business registers solid growth on the continued adoption of MiniMed 670G in overseas markets.
Myriad Genetics' (MYGN) BRACAnalysis Gets Japan Reimbursement
by Zacks Equity Research
Myriad Genetics (MYGN) launches BRACAnalysis Diagnostic System in Japan, after receiving reimbursement for the system, which will enable easier identification of HBOC patients.
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its strong segmental growth in the fourth quarter of 2019.